Knowledge Hub
Information you can trust.
Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.
15 resources
Page 1 of 1
Understanding NET cancer1 Jul 2026SCAN 2025 – NET patient survey (New Zealand)
The New Zealand reading of the global SCAN 2025 survey of neuroendocrine cancer patients and clinicians – how our care compares with the world.
Read
Understanding NET cancer22 Jul 2026MEN1 syndrome (Multiple Endocrine Neoplasia type 1)
MEN1 is a rare inherited condition that causes tumours in the endocrine glands – the parathyroids, pituitary and pancreas. What it is, what causes it, and how it is diagnosed.
Read
Understanding NET cancer20 Mar 2026Types of scans for NET Cancers
There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.
Read
Understanding NET cancer20 Mar 2026Grades of Neuroendocrine (NET) Cancers
What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.
Read
Understanding NET cancer20 Mar 2026Types of Neuroendocrine Tumours
Neuroendocrine Tumours (NETs) is an umbrella name for a number of different types of tumours, which can arise in different areas of the body. It can be…
Read
Understanding NET cancer16 Mar 2026Treatments for NETs
Treatments for neuroendocrine cancers vary from person to person and may be one or more of the options listed below.
Read
Understanding NET cancer12 Mar 2026A second PRRT in the FDA pipeline: 177Lu-edotreotide decision due August 2026
The FDA is expected to decide on ITM-11 (177Lu-edotreotide) for GEP-NETs by 28 August 2026, based on the Phase 3 COMPETE trial results.
Read
Understanding NET cancer20 Jan 2026Early signals from alpha-emitter PRRT in SSTR2-positive NETs
A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.
Read- Understanding NET cancer20 Jan 2026
Understanding Neuroendocrine
Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.
Read - Understanding NET cancer26 Mar 2025
Cabozantinib approved by the FDA for previously treated advanced NETs
The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.
Read - Understanding NET cancer15 Sept 2024
NETTER-2 supports PRRT as a first-line option in advanced GEP-NETs
The Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.
Read - Understanding NET cancer1 Jun 2024
When NET cancers run in families: inherited syndromes
Most neuroendocrine cancers aren't inherited, but a small number are linked to hereditary syndromes like MEN1, MEN2 and VHL. Here's what to know.
Read - Understanding NET cancer15 Jan 2024
Understanding Neuroendocrine (NET) Cancers
Neuroendocrince Cancer NZ is an organisation dedicated to revolutionising the way that neuroendocrine tumours are diagnosed and managed in New Zealand.
Read 
Understanding NET cancer1 Jun 2023NET Resources
Revisit past presentations from NET Cancer specialists at Unicorn Foundation NZ's NET Cancer Education Days.
Read- Understanding NET cancer15 Jul 2021
PRRT in NZ
Neuroendocrince Cancer NZ is an organisation dedicated to revolutionising the way that neuroendocrine tumours are diagnosed and managed in New Zealand.
Read